Phaxiam: encouraging clinical results

(CercleFinance.com) - Phaxiam Therapeutics announces encouraging clinical results from the non-comparative PhagoDAIR I pilot study in patients with S.
aureus infection of hip or knee prostheses.

This randomized, multicenter, double-blind study initially planned to include 64 patients, but due to overly restrictive selection criteria, only 29 patients were randomized, of whom 26 were evaluable for clinical activity.

Phaxiam reports an excellent phage safety profile and, for patients who received a single intra-articular injection, a 74% infection control rate for the phage arm, consistent with that seen in patients treated under compassionate status.

The biopharmaceutical company is now focusing on the GLORIA Phase II trial, which plans to enrol 100 patients in Europe and the United States from the first quarter of 2025, using criteria that have been broadened in comparison with PhagoDAIR.

Copyright (c) 2024 CercleFinance.com. All rights reserved.